Healthcare

Liquid Biopsy Market Revenue, Global Presence, and Strategic Insights by 2034

December 3, 2025December 3, 2025 by Rutuja Borkar

Table of Contents

Liquid Biopsy Market Size

The global liquid biopsy market size was worth USD 10.97 billion in 2024 and is anticipated to expand to around USD 31.28 billion by 2034, registering a compound annual growth rate (CAGR) of 11.05% from 2025 to 2034.

What Is the Liquid Biopsy Market?

The liquid biopsy market includes the tools, assays, laboratory services, and data interpretation platforms used to detect cancer-related biomarkers from non-invasive sources such as blood, urine, saliva, and cerebrospinal fluid. Instead of relying on traditional tissue biopsies—which can be invasive, risky, and limited by tumor heterogeneity—liquid biopsy analyzes fragments of tumor-derived material circulating in bodily fluids.

This market comprises:

ctDNA-based sequencing tests
Circulating tumor cell (CTC) detection platforms
Exosome and extracellular vesicle assays
NGS platforms and molecular diagnostic systems
Sample preparation kits and reagents
Bioinformatics tools and cloud-based interpretation platforms

The market serves oncologists, hospitals, reference laboratories, pharmaceutical companies, precision-medicine clinics, and academic research institutions. As adoption expands across diagnostic, monitoring, and screening applications, liquid biopsy is becoming a central pillar of modern oncology diagnostics.

Get a Free Sample: https://www.cervicornconsulting.com/sample/2401

Why Is Liquid Biopsy Important?

Liquid biopsy is important because it addresses the shortcomings of tissue biopsies—limited sample quantity, patient discomfort, procedural risk, and inability to capture real-time tumor evolution. Liquid biopsy offers:

1. Non-Invasive and Repeatable Testing

Patients can undergo tests frequently, enabling continuous monitoring of disease progression or relapse.

2. Early Detection

Ultra-sensitive ctDNA assays can identify cancers earlier than imaging or symptoms, supporting multi-cancer early detection (MCED) frameworks.

3. Comprehensive Tumor Profiling

Liquid biopsy captures mutations from multiple tumor sites at once, providing a more complete genomic picture.

4. Companion Diagnostics Integration

Many targeted therapies require molecular profiling; liquid biopsy enables tumor mutation detection even when tissue is unavailable.

5. Minimal Residual Disease (MRD) Monitoring

Detects tiny traces of cancer remaining after therapy, enabling earlier intervention.

6. Accelerated Clinical Trials

Biopharma uses liquid biopsy for patient selection, pharmacodynamics, and real-time monitoring, shortening trial timelines.

These capabilities make liquid biopsy essential to precision oncology, preventive screening, and next-generation drug development.

Liquid Biopsy Market Growth Factors

The liquid biopsy market is expanding rapidly due to rising global cancer incidence, increasing focus on early detection, greater use of precision medicine, and major technological advancements in ctDNA analysis, NGS platforms, and bioinformatics. Growing evidence supporting the clinical utility of liquid biopsy in therapy selection, MRD monitoring, and multi-cancer screening has accelerated adoption among hospitals and oncologists.

Biopharma companies are increasingly integrating liquid biopsy into clinical trials for patient stratification and endpoint evaluation, while government initiatives, public screening programs, and improving reimbursement frameworks are further driving growth. Declining sequencing costs, broader clinical approvals, and expanding applications beyond oncology—such as prenatal testing and transplant surveillance—add to the market’s momentum, establishing liquid biopsy as one of the fastest-growing diagnostic sectors worldwide.

Top Companies in the Liquid Biopsy Market (2024)

Below are detailed profiles of the leading players you requested, including their specializations, key focus areas, notable features, 2024 revenue snapshots, market influence, and global presence.

1. Guardant Health

Specialization:
ctDNA-based oncology liquid biopsy tests, including genomic profiling, MRD testing, and emerging screening solutions.

Key Focus Areas:

Tumor profiling via Guardant360
Treatment selection for metastatic cancers
Cancer screening through Guardant Shield
Biopharma services and real-world evidence programs

Notable Features:

Leader in clinical ctDNA testing in the U.S.
Strong data analytics and longitudinal patient datasets
Rapidly expanding screening and MRD test portfolio

2024 Revenue:
Approximately USD 737 million (significant annual growth).

Market Position & Global Presence:
A top-tier commercial liquid biopsy leader with operations and partnerships across North America, Europe, and Asia.

2. Illumina, Inc.

Specialization:
NGS sequencing platforms that power many global liquid biopsy workflows.

Key Focus Areas:

NGS sequencers and consumables
Oncology sequencing partnerships
Library prep kits and workflow automation

Notable Features:
Illumina is the backbone technology provider for many liquid biopsy companies, making it foundational to the ecosystem.

2024 Revenue:
Around USD 4.3 billion across its core sequencing business (company-wide, not liquid biopsy-specific).

Market Position & Global Presence:
Global leader in sequencing technology with a presence in nearly every major diagnostic and research lab worldwide.

3. Biocept, Inc.

Specialization:
Circulating tumor cell (CTC) assays and targeted molecular testing.

Key Focus Areas:

CTC collection and analysis
Molecular oncology lab services
Niche clinical segments

Notable Features:
A smaller but specialized player focused primarily on CTC technology rather than broad NGS-based testing.

2024 Revenue:
Low single-digit million-dollar range; significantly smaller than major competitors.

Market Position & Global Presence:
Niche U.S.-based participant with focused oncology offerings.

4. QIAGEN N.V.

Specialization:
Sample preparation kits, PCR assays, NGS workflows, and diagnostics used widely in liquid biopsy laboratories.

Key Focus Areas:

Diagnostic instrumentation
NGS panels and PCR testing
Precision oncology

Notable Features:
QIAGEN’s technologies support extraction, enrichment, and analysis across the liquid biopsy workflow.

2024 Revenue:
Approximately USD 1.9–2.0 billion in total company net sales.

Market Position & Global Presence:
Strong global footprint with particularly high adoption in Europe and North America.

5. Roche Diagnostics

Specialization:
Global diagnostics systems, companion diagnostics, and oncology testing solutions; includes capabilities from Foundation Medicine.

Key Focus Areas:

Molecular diagnostics
Oncology genomic profiling
Hospital-integrated diagnostic systems

Notable Features:
Extensive commercial and clinical infrastructure; historically acquired Foundation Medicine to expand liquid biopsy offerings.

2024 Diagnostics Revenue:
Approximately CHF 14.3 billion across the diagnostics division.

Market Position & Global Presence:
One of the world’s largest diagnostics companies, with direct presence in 100+ countries.

Leading Trends in the Liquid Biopsy Market & Their Impact

1. Rise of Multi-Cancer Early Detection (MCED)

Advanced blood-based tests for early cancer detection are gaining global traction. Their success could transform national screening strategies and significantly expand the market.

2. High-Sensitivity MRD Monitoring

Hospitals increasingly adopt MRD liquid biopsy tests to identify relapse months before imaging. This drives repeat testing, boosting long-term market value.

3. Rapid Advancements in NGS & Error Suppression

Ultra-high-depth sequencing and better bioinformatics pipelines improve test accuracy, enabling earlier-stage detection.

4. Growing Pharma–Diagnostics Partnerships

Biopharma companies collaborate with diagnostic firms to co-develop ctDNA companion diagnostics, accelerating clinical adoption.

5. Integration of AI and Genomic Data

AI enhances mutation interpretation, tissue-of-origin prediction, and risk stratification, creating competitive differentiation for companies with strong data capabilities.

6. Expanding Use Cases Beyond Oncology

Potential markets include:

Organ transplant rejection monitoring
Prenatal screening
Infectious disease genomics
These adjacent opportunities broaden the market’s addressable scope.

Successful Global Examples of Liquid Biopsy Adoption

United States

Liquid biopsy is deeply integrated into oncology workflows, especially for genomic profiling in lung, colorectal, and breast cancers. Guardant Health’s Guardant360 test is a widely used example for treatment selection. Screening studies and MRD testing are rapidly expanding.

United Kingdom

The UK has been running large-scale cancer screening pilots using advanced liquid biopsy platforms, evaluating cost-effectiveness and clinical outcomes for use in population-level programs.

Europe

Multiple countries are incorporating ctDNA-based diagnostics into national precision oncology initiatives, supporting clinical validation and reimbursement.

China & Asia Pacific

Hospitals widely use ctDNA tests for EGFR, ALK, KRAS, and other mutations. Domestic genomic companies develop locally tailored assays, supported by government-backed precision medicine initiatives.

Pharmaceutical Trials Worldwide

Liquid biopsy is now common in oncology drug development for:

Patient mutation screening
Assessing treatment response
Monitoring disease evolution

This has driven large-scale adoption across global research networks.